Singh Biotechnology, LLC was accepted into the Tampa Bay Technology Incubator (TBTI) at the University of South Florida. "It exists to support technology research as a catalyst for economic development and advocates the development and construction of facilities for high-technology companies and related support functions."
FDA Grants Orphan Drug Designation to SBT-100 for Pancreatic Cancer
Singh Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody (sdAb) for the treatment of pancreatic cancer. Many studies have found that elevated STAT3 expression is associated with a poor prognosis of solid tumors, including tumor of the pancreas. STAT3 can be inhibited either by directly targeting the intracellular protein or indirectly, by targeting the upstream regulators of the STAT3 pathway.
Science is a way of thinking much more than it is a body of knowledge.